[NTD, Beijing time, August 2, 2022]At the beginning of July, a study by Jikeikai Medical University in Tokyo, Japan found that the original treatment for cancer “”photoimmunotherapywhich can be used to killbacteria、fungusand the current CCP virus (COVID-19).
The research team of The Jikei University School of Medicine in Tokyo, Japan, with a history of 140 years, reported on July 4 in “science magazine“(Nature) published an article about “photoimmunotherapy” (PIAS) latest report.
The report said that the use of this therapy inbacteria、fungusAnd with the COVID-19 virus, it was found to work well, regardless of whether those targets were drug-resistant (drug-resistant).
Originally, photoimmunotherapy was used to treat cancer. It was officially approved by the Japanese government in 2020. It kills cancer cells through drugs and medical devices and irradiates lasers outside the body. It is currently used to treat head and neck cancer patients.
The research team stated in the report that due to the increase in people’s abuse and dependence on drugs, microorganisms are rapidly becoming resistant to newly developed drugs (such as antibiotics) in humans, and new drug development time is often missed for a long time. The optimal timing of treatment makes the means of treating infection more complicated and difficult.
The report pointed out that in 2019 alone, 4.95 million deaths worldwide were linked to bacterial resistance, making it one of the leading causes of death globally.
Research team sets out to target bacterial pathogens’Staphylococcus aureus” (Staphylococcus aureus, SA), the fungal pathogen Candida albicans (Candida albicans, CA) and the COVID-19 virus. The first two germs are common and multidrug-resistant microbes, and the COVID-19 virus is constantly mutating, making it difficult for hospitals to treat infected people.
In the experiment, theyStaphylococcus aureus(including drug-resistant ones), make an SA-IR700 antibody, and let them fuse. And using scanning electron microscopy to confirm their binding, found that they can be well together.
Therefore, the researchers combined methicillin-resistant Staphylococcus aureus (MRSA) with SA-IR700 antibody and put it into the nasal cavity of mice together, and released near-infrared light with a wavelength of 670 nanometers to 710 nanometers through light-emitting diodes ( NIR) penetrates the deep tissue of mice, stimulates SA-IR700 antibody to make it work, and observes whether the number of bacteria decreases to determine whether the expected bactericidal effect is achieved.
The results showed that about 90 percent of the drug-resistant Staphylococcus aureus bacteria died in just a few minutes, but did not destroy the host’s microbiota and body tissues, because the normal flora in the mice’s guts was unchallenged and functioning. normal. This proves that photoimmunotherapy can protect mice from lethal infection without harming the subject, showing a good therapeutic effect.
In addition to the MRSA test, the experiment also tested other resistant Staphylococcus aureus with no difference, and photoimmunotherapy can act on Staphylococcus aureus cells under various conditions, including Petri dishes with different conditions middle.
In addition, experiments have found that the speed of photoimmunotherapy killing Staphylococcus aureus is highly positively correlated with the amount of near-infrared light and antibody dose, which can accelerate the killing of these bacteria within a certain range.
They also experimented with photoimmunotherapy on normal bacterial groups, including those with a symbiotic relationship with humans, Staphylococcus epidermidis, and with animals, Staphylococcus microti, but did not observe obvious effect.
Scientists say the SA-IR700 antibody is more difficult to bind to these normal bacteria, thus showing that the therapy can target and kill Staphylococcus aureus (including drug resistance).
In the next experiment, they combined antibodies against the fungal pathogen Candida albicans to CA-IR700 and used photoimmunotherapy (irradiation with near-infrared light) to destroy and eliminate it. The results showed that the target fungus could be eliminated very effectively, regardless of whether the target fungus was drug-resistant or not.
This method has no effect on normal fungi such as Candida stelaeus and Saccharomyces cerevisiae. The experimental results show that the method is targeted for fungi. If CA-IR700, SA-IR700 and methicillin-resistant Staphylococcus aureus and Candida albicans are mixed together, the desired results can also be obtained.
In the last experiment, in order to confirm whether photoimmunotherapy can kill the COVID-19 virus, antibodies to Pan-IR700, SC-IR700#1, SC-IR700#2, SC-IR700#3 and SC-IR700#4 were made , and also irradiated with near-infrared light.
The results show that SC-IR700#1 can effectively inactivate the virus, while SC-IR700#2 and SC-IR700#3 can also inactivate the virus, but SC-IR700#4 and Pan-IR700 have no significant utility. Scientists speculate that it may be related to their specificity, so it did not play a role.
The report concludes that this is the first demonstration of an effect on common pathogens such as bacteria, fungi and viruses. If an antibody is found to bind to a pathogen, it may be possible to create a drug and method that is effective against the pathogen.
Masato Mitsunaga, a lecturer (gastroenterology and hepatology) at Tokyo’s Jikekai Medical University, a member of the research team, told Japan’s “Mainichi Shimbun” on July 15, “This treatment is expected to reduce the number of complications associated with treatment. side effects, because it can treat those pathogens that are drug-resistant or extreme, and it doesn’t affect the functioning of normal cells.”
(Transfer from The Epoch Times/Editor-in-charge: Ye Ping)
URL of this article: https://www.ntdtv.com/b5/2022/08/01/a103491986.html